摘要
目的研究替比夫定与恩替卡韦治疗HBeAg阳性慢性乙型肝炎的效果。方法选取我院2013年6月~2015年6月期间收治的HBeAg阳性慢性乙型肝炎患者共计40例,按照随机数字表法分为甲组(n=20)和乙组(n=20),甲组患者使用替比夫定治疗,乙组患者使用恩替卡韦治疗,对比分析两组患者的HBeAg血清转换率、ALT复常率及不良反应发生情况。结果在HBeAg血清转换率对比中,除却甲乙两组在治疗前、4周、12周、28周HBeAg血清转换率比较差异无统计学意义(P>0.05),甲组患者在52周、72周HBeAg血清转换率均高于乙组,经统计学比较差异有统计学意义(P<0.05);在ALT复常率对比中,甲组患者治疗前及治疗后各时间段的ALT复常率与乙组相比均无明显差异,组间比较差异无统计学意义(P>0.05);在不良反应发生情况对比中,两组患者在治疗后28周、52周、72周不良反应发生差异有统计学意义(P<0.05)。结论替比夫定与恩替卡韦均对HBeAg阳性慢性乙型肝炎患者起到较好的抗病毒效果,替比夫定对患者HBeAg血清学转换率治疗效果更好,远期来看不良反应相对较多,但不会造成肾损伤,具有较好的临床应用价值。
Objective To study the efficacy of tibivudine and entecavir in the treatment of HBeAg positive chronic hepatitis B. Methods A total of 40 HBeAg positive patients with chronic hepatitis B were selected from June 2013 to June 2015 in our hospital.According to the random number table method,they were divided into two groups：group A（n=20） and group B（n=20）.Patients in group A were treated with tibivudine,and patients in group B were treated with entecavir.The HBeAg seroconversion rate,ALT recurrence rate and the incidence of adverse reactions were compared between the two groups. Results In the comparison of HBeAg seroconversion rate,there was no significant difference in HBeAg seroconversion rate between the two groups before treatment and after 4 weeks and 12 weeks and 28 weeks after treatment（P 0.05）.The seroconversion rate of HBeAg in group A was significantly higher than that in group B at 52 weeks and 72 weeks（P 0.05）.There was no significant difference in ALT recovery rate between group A and group B before and after treatment（P 0.05）.There were significant differences in the incidence of adverse reactions between the two groups at 28 weeks,52 weeks and 72 weeks after treatment（P 0.05）. Conclusion Both tibivudine and entecavir had better antiviral effect on HBeAg positive patients with chronic hepatitis B,tibivudine had better effect on HBeAg serological conversion rate,and in the long run there were more adverse reactions,but will not cause kidney injury, has the good clinical application value.
作者
陈廷宪
罗贤鑫
莫思柏
CHEN Tingxian;LUO Xianxin;MO Sibai(Public Health Hospital,Yangjiang 529500,Chin)
出处
《中国医药科学》
2018年第8期46-48,共3页
China Medicine And Pharmacy
